4.8 Article

Human and preclinical studies of the host-gut microbiome co-metabolite hippurate as a marker and mediator of metabolic health

期刊

GUT
卷 70, 期 11, 页码 2105-2114

出版社

BMJ PUBLISHING GROUP
DOI: 10.1136/gutjnl-2020-323314

关键词

intestinal microbiology; glucose metabolism; obesity; colonic microflora

资金

  1. FP7 METACARDIS HEALTH-F4-2012 [305312]
  2. Metagenopolis grant [ANR-11-DPBS-0001]
  3. NIHR Imperial Biomedical Research Centre
  4. French National Research Agency [ANR-10-LABX-46]
  5. National Center for Precision Diabetic Medicine -PreciDIAB - French National Agency for Research [ANR-18-IBHU-0001]
  6. National Center for Precision Diabetic Medicine -PreciDIAB - European Union (FEDER)
  7. National Center for Precision Diabetic Medicine -PreciDIAB - Hauts-de-France Regional Council [20002845]
  8. National Center for Precision Diabetic Medicine -PreciDIAB - European Metropolis of Lille (MEL)
  9. Isite ULNE [R-002-20-TALENT-DUMAS]
  10. ANR [ANR-16-IDEX-0004-ULNE]
  11. European Metropolis of Lille (MEL)
  12. Marie Curie Actions FP7 People COFUND [267 139]
  13. Fund for Scientific Research-Flanders (FWO-V)
  14. Novo Nordisk Foundation [NNF18CC0034900]
  15. MRC [MR/L01632X/1] Funding Source: UKRI

向作者/读者索取更多资源

The urine concentration of hippurate positively correlates with microbial gene richness and functional modules for microbial benzoate biosynthetic pathways. In individuals consuming a diet rich in saturated fat, hippurate concentration independently of gene richness is associated with metabolic health. In high-fat-fed mice, chronic infusion of hippurate leads to improved glucose tolerance and enhanced insulin secretion, demonstrating its role as a potential mediator of metabolic health.
Objective Gut microbial products are involved in regulation of host metabolism. In human and experimental studies, we explored the potential role of hippurate, a hepatic phase 2 conjugation product of microbial benzoate, as a marker and mediator of metabolic health. Design In 271 middle-aged non-diabetic Danish individuals, who were stratified on habitual dietary intake, we applied H-1-nuclear magnetic resonance (NMR) spectroscopy of urine samples and shotgun-sequencing-based metagenomics of the gut microbiome to explore links between the urine level of hippurate, measures of the gut microbiome, dietary fat and markers of metabolic health. In mechanistic experiments with chronic subcutaneous infusion of hippurate to high-fat-diet-fed obese mice, we tested for causality between hippurate and metabolic phenotypes. Results In the human study, we showed that urine hippurate positively associates with microbial gene richness and functional modules for microbial benzoate biosynthetic pathways, one of which is less prevalent in the Bacteroides 2 enterotype compared with Ruminococcaceae or Prevotella enterotypes. Through dietary stratification, we identify a subset of study participants consuming a diet rich in saturated fat in which urine hippurate concentration, independently of gene richness, accounts for links with metabolic health. In the high-fat-fed mice experiments, we demonstrate causality through chronic infusion of hippurate (20 nmol/day) resulting in improved glucose tolerance and enhanced insulin secretion. Conclusion Our human and experimental studies show that a high urine hippurate concentration is a general marker of metabolic health, and in the context of obesity induced by high-fat diets, hippurate contributes to metabolic improvements, highlighting its potential as a mediator of metabolic health.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据